The Market For DNA-Sequencing-Based Down Syndrome Tests Could Exceed $6 Billion - Don't Screen Us Out

The Market For DNA-Sequencing-Based Down Syndrome Tests Could Exceed $6 Billion

Jan 28, 2014 | Media

On Wednesday night the New England Journal of Medicine published a study showing that a new, DNA-sequencing based blood test provides a dramatic improvement in accuracy at screening for Down syndrome and a second, deadly disorder. That could open up a $6 billion market to the biotechnology companies that are already marketing these tests.

Each year in the U.S. there are 6.6 million pregnancies and 4 million births, according the Centers for Disease Control & Prevention. The list prices of the tests, which are sold by four different companies, range from $700 to $2500. Assuming that pricing settles in the middle of that range and that there are 5 million women who choose to have the test, that would be a $8 billion market.

To read the full article click here.

keep up to date

with the latest campaign developments and find out how you can help create a world where people with Down’s syndrome are equally valued

Follow us

FacebookYoutubeTikTokInstagramTwitter

latest media

Join us outside the High Court on Thursday

I hope you are well. At 10:30am on Thursday (23 September) the High Court will be releasing their decision on Heidi Crowter and Máire Lea-Wilson's landmark case against the UK Government. We are going to be meeting at 9:30am outside the High Court to show support for...

Don’t Screen Us Out launch new website for their community

Press release for immediate release Don’t Screen Us Out launch new website for their community Down’s syndrome advocacy group Don’t Screen Us Out have, this evening, launched a new website. Don’t Screen Us Out is a group of over 17,000 people with Down’s syndrome,...

Share this page:

Related